VIR insider sale after restricted stock vesting

VIR: Notice of proposed insider sale following restricted stock vesting.

Accepted by SEC EDGAR 02/24/2026 - 04:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

VIR: Notice of proposed insider sale following restricted stock vesting. The filing reports 1,634 restricted common shares vested on 02/23/2026 as issuer compensation. It also discloses that Jason V. O'Byrne sold 2,089 common shares on 02/23/2026 for $15,568.90.

Insights

Corporate Governance / Insider Transactions

Form 144 shows a vesting event and an associated insider sale on 02/23/2026.

The notice lists 1,634 restricted common shares vesting as issuer compensation on 02/23/2026, and separately records a sale of 2,089 common shares by Jason V. O'Byrne for $15,568.90. These are routine issuer compensation and reported dispositions.

Timing and cash‑flow treatment are explicit for the sale; further disclosures in subsequent filings would be needed to assess any broader dilution or plan impacts.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did VIR disclose about restricted stock on 02/23/2026?

The filing states 1,634 restricted common shares vested on 02/23/2026. This item is described as issuer compensation related to restricted stock vesting reported on that date.

How many shares did Jason V. O'Byrne sell in the past three months (VIR)?

The filing reports Jason V. O'Byrne sold 2,089 common shares on 02/23/2026 for $15,568.90. This sale appears in the "Securities Sold During The Past 3 Months" section.

Does the Form 144 indicate who received proceeds from the sale (VIR)?

The filing attributes the reported sale to Jason V. O'Byrne on 02/23/2026 for $15,568.90. The document does not specify any alternate recipient of proceeds.

Is the 1,634-share vesting item described as compensation for VIR?

Yes; the entry lists the 1,634 common shares as Restricted Stock Vesting and labels the transaction purpose as Compensation with an event date of 02/23/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001871145
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	O'Byrne Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1634	15576.27	139517278	02/24/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/23/2026	Restricted Stock Vesting	Issuer			1634	02/23/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason V. O'Byrne 1800 Owens Street Suite 900 San Francisco CA 94158	Common	02/23/2026	2089	15568.90

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Audrey McMillen, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jason O'Byrne
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)